Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, ≥12 years of age with weight at least 40 kg~* Diagnosed with severe hemophilia A, defined as \<1 IU/dL (\<1%) endogenous Factor VIII)~* History of at least 150 documented prior exposure days to any Factor VIII product~* Platelet count ≥100,000 cells/μL~Exclusion Criteria:~* History of Factor VIII inhibitors~* Kidney and liver dysfunction~* Diagnosed with other coagulation disorder(s) in addition to hemophilia A~* Prior history of hypersensitivity or anaphylaxis associated with any FVIII or IV immunoglobulin administration

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individualized (Tailored) Prophylaxis (Type: EXPERIMENTAL): On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A \>= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity.
- Weekly Prophylaxis (Type: EXPERIMENTAL): 65 IU/kg of rFVIIIFc via IV injection every 7 days
- Episodic (On-Demand) Dosing (Type: EXPERIMENTAL): 10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode

Based on this trial design, predict the completion outcome and termination type (if applicable).